Congressional disclosures have produced a fresh set of standout buys that delivered exceptional performance once they entered the public record. The data shows multiple House members whose timely filings in healthcare, technology and related sectors turned into triple and quadruple digit returns for any investor who reviewed them on or after the disclosure date. These returns are measured from the DISCLOSURE date forward and the public could have seen each of these positions when they were filed.
Rep. Ro Khanna, D-CA, purchased MRNA with a transaction dated January 12, 2025. The position was disclosed January 6, 2026. This MRNA buy is an outlier we are still verifying rather than a figure we assert at this time. Rep. Lisa McClain, R-MI, bought SNDK disclosed on November 21, 2025. That position is likewise an outlier we are still verifying. Both trades fell in the $1,001-$15,000 range yet sit at the top of our current performance list.
Among fully verified positions, Khanna also disclosed a MU purchase on November 6, 2025 that has returned 457.22 percent since filing. Rep. Tim Moore, R-NC, disclosed his TZA buy on July 9, 2025, now showing a 305.85 percent gain. McClain added another verified winner with ROIV disclosed August 13, 2025 and up 254.59 percent. Rounding out the list, Rep. Gilbert Cisneros, D-CA, disclosed an SEI purchase on June 6, 2025 that returned 184.16 percent.
The four lawmakers collectively placed these six buys across healthcare and technology names plus a leveraged small-cap instrument and an energy infrastructure play. Each filing was available on senate.gov or clerk.house.gov the day it was submitted, allowing any retail investor to incorporate the exact tickers, dates and size ranges into their own process. Our conviction scores and cluster signals flagged several of these names in real time, yet the true test came in the subsequent price action measured strictly from disclosure forward.
With days-held ranging from 381 to 730, these trades underscore how disclosure timing itself can serve as a viable starting point for independent analysis. While no single cluster guarantees repetition, the verified outperformance in MU, TZA, ROIV and SEI alongside the two outliers still under review adds to the accumulating record of post-filing alpha in our congressional dataset. New filings continue to arrive weekly and warrant the same disciplined review from the disclosure date.
This is data analysis, not financial advice.
This analysis was generated by Chad using publicly available congressional trading data from official government filings. This is not financial advice. All data is sourced from senate.gov, clerk.house.gov, and SEC EDGAR.